Recovery

MuskelkaterStudienlage & Dosis

Delayed Onset Muscle Soreness — Mechanismus, was hilft, was nicht.

Studienlage in Zahlen

Studien gesamt: 634
Mit Abstract: 37
Meta / Systematic / RCT: 7
Häufig zitiert: 19
Erscheinungsjahre: 1968–2026

Muskelkater im Kontext von Recovery

Dieses Thema ist Teil unserer Welt „Recovery". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Recovery

Top-Studien zu Muskelkater

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
JAMA network open2024n=195200 einflussreiche Zitationen
<h4>Importance</h4>A major concern with weight loss is concomitant bone loss. Exercise and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent weight loss strategies that may protect bone mass despite weight…
Hyperglycaemic crises in adults with diabetes: a consensus report.
Diabetologia2024200 einflussreiche Zitationen
The American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), Joint British Diabetes Societies for Inpatient Care (JBDS), American Association of Clinical Endocrinology (AACE) and Diabetes Technology…
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes Obes Metab2025n=160rct200 einflussreiche Zitationen
AIMS: We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT-1 trial, overall and post hoc in clinically relevant subgroups. MATERIALS AND METHODS:…
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.
American journal of preventive cardiology2024n=83.258175 einflussreiche Zitationen
<h4>Background</h4>Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular…
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
JAMA surgery2023n=70170 einflussreiche Zitationen
Importance Metabolic surgery leads to weight loss and improved health, but these outcomes are highly variable. Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1). Objective To assess the…
Dose-response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia2024n=413166 einflussreiche Zitationen
<h4>Aims/hypothesis</h4>The aim of this study was to assess the dose-response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA<sub>1c</sub> levels and bodyweight…
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.
JAMA network open2024n=834156 einflussreiche Zitationen
<h4>Importance</h4>Despite its demonstrated benefits in improving cardiovascular risk profiles, the association of tirzepatide with mortality and cardiovascular and kidney outcomes compared with glucagon-like peptide 1 receptor agonists…
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
JAMA network open2024155 einflussreiche Zitationen
<h4>Importance</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.<h4>Objectives</h4>To…
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
JAMA2023n=1.428149 einflussreiche Zitationen
Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of adding tirzepatide vs prandial insulin to treatment in…
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
JAMA network open2023n=411141 einflussreiche Zitationen
Importance Currently available glucagon-like peptide 1 receptor (GLP-1R) agonists for treating type 2 diabetes (T2D) are peptide agonists that require subcutaneous administration or strict fasting requirements before and after oral…